GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Total Inventories

Bioasis Technologies (FRA:107) Total Inventories : €0.00 Mil (As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Total Inventories?

Bioasis Technologies's total inventories for the quarter that ended in Nov. 2022 was €0.00 Mil. Bioasis Technologies's average total inventories from the quarter that ended in Aug. 2022 to the quarter that ended in Nov. 2022 was €0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bioasis Technologies's Net-Net Working Capital per share for the quarter that ended in Nov. 2022 was €-0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Bioasis Technologies's Inventory-to-Revenue for the quarter that ended in Nov. 2022 was 0.00.


Bioasis Technologies Total Inventories Historical Data

The historical data trend for Bioasis Technologies's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Total Inventories Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bioasis Technologies Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Bioasis Technologies  (FRA:107) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Bioasis Technologies's Net-Net Working Capital Per Share for the quarter that ended in Nov. 2022 is

Net-Net Working Capital Per Share (Q: Nov. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.114+0.75 * 0.01+0.5 * 0-3.251
-0-0)/79.414
=-0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bioasis Technologies's Days Inventory for the three months ended in Nov. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Nov. 2022 )/Cost of Goods Sold (Q: Nov. 2022 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bioasis Technologies's Inventory Turnover for the quarter that ended in Nov. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Nov. 2022 ) / Average Total Inventories (Q: Nov. 2022 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bioasis Technologies's Inventory to Revenue for the quarter that ended in Nov. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Nov. 2022 ) / Revenue (Q: Nov. 2022 )
=0 / 0.109
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Bioasis Technologies Total Inventories Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (FRA:107) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines